Iovance Biotherapeutics, Inc.
IOVA
Classificação em ações
#2785
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Preço da ação
$14.87
Valor de mercado
$6.74B
Variação (1 dia)
4.64%
Variação (1 ano)
540.91%
País
US
Negociar Iovance Biotherapeutics, Inc. (IOVA)
Categoria
Healthcare
Rácio P/S de Iovance Biotherapeutics, Inc. (IOVA)
Rácio P/S em October 2026 TTM: 19.81
De acordo com os relatórios financeiros mais recentes e o preço das ações da Iovance Biotherapeutics, Inc., o rácio P/S atual (TTM) é 19.81. No final de 2023, o rácio P/S era 1.61K.
Histórico do rácio P/S da Iovance Biotherapeutics, Inc. de 2008 a 2026
Rácio P/S no final de cada ano
| Ano | Rácio P/S | Alterar |
|---|---|---|
| 2026 (TTM) | 19.81 | 51.55% |
| 2024 | 13.07 | -99.19% |
| 2023 | 1.61K | 0.00% |
| 2022 | 0.00 | 0.00% |
| 2021 | 0.00 | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | 0.00% |
| 2010 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
Rácio P/S de empresas semelhantes ou concorrentes
| Empresa | Rácio P/S | Diferença do rácio P/S | País |
|---|---|---|---|
| 10.02 | -49.40% |
US
|
|
| 40.55 | 104.73% |
US
|
|
| 3.96 | -80.00% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | -48.77% |
NL
|
